Competition - OHE

Click here

Office of Health Economics

Leading intellectual authority on global health economics

Search publications, topics, authors and more

Newsletter SignupSubscribe

News & Insights

News
Events
Insights
Bulletin

News
Events
Insights
Bulletin

Click here

News & Insights

News
Events
Insights
Bulletin

Newsletter SignupSubscribe

News
Events
Insights
Bulletin

Search publications, topics, authors and more

Research & Publications
News & Insights
Education
Innovation Policy Prize

Events
About Us
OHE Experts
Join OHE
Contact Us

Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:

Antimicrobial Resistance (AMR)
Biosimilars
Cell and Gene Therapies
Chronic Diseases
Combination Therapies
COVID-19 Research
Digital Health
Drug Development/R&D
Emerging Markets
EQ-5D and PROMs
Health Care Systems
Health Data and Statistics
Health Technology Assessment
Precision Medicine
Prevention
Real-World Evidence
Sustainability
Use of Medicines
Value-Based Pricing
Vaccine Research

Economics of Innovation
Measuring and Valuing Outcomes
Policy, Organisation and Incentives in Health Systems
Value, Affordability and Decision Making

News & Insights

News
Events
Insights
Bulletin

Education

Education Hub
OHE Graduate School
EVIA Programme

Innovation Policy Prize

The Prize Fund
2024 Prize Fund
2022 Prize Fund

Search publications, topics, authors and more

Latest Research & Publications

EQ-5D and PROMs
Measuring and Valuing Outcomes
Clinical Outcomes

Anchoring Latent Scale Values for the EQ-5D-Y at 0 = Dead

Antimicrobial Resistance (AMR)
Value, Affordability, and…
Generics

HTA and Payment Mechanisms for New Drugs to Tackle AMR

Health Data and Statistics
Economics of Innovation

Data Governance Arrangements for Real-World Evidence in Japan

Policy, Organisation and…
Injury and Trauma

Unrelieved Pain in Palliative Care in England

Health Technology Assessment…
Economics of Innovation
Determining Value

The Case of Risperidone: Assessing the Life-cycle Value of Second-Generation Antipsychotics in Sweden and the UK

EQ-5D and PROMs
Measuring and Valuing Outcomes
Clinical Outcomes

Valuing EQ-5D-Y Health States Using a Discrete Choice Experiment: Do Adult and Adolescent Preferences Differ?

Value-Based Pricing
Economics of Innovation
Health Policy and Regulation

Documento de debate sobre la fijación de precios en función de la indicación (IBP) ¿Deben variar los precios de los medicamentos según la indicación?

All Publications

Filter by:

Antimicrobial Resistance (AMR)

Biosimilars

Cell and Gene Therapies

Chronic Diseases

Combination Therapies

COVID-19 Research

Digital Health

Drug Development/R&D

Emerging Markets

EQ-5D and PROMs

Health Care Systems

Health Data and Statistics

Health Technology Assessment

Precision Medicine

Prevention

Real-World Evidence

Sustainability

Use of Medicines

Value-Based Pricing

Vaccine Research

Economics of Innovation

Measuring and Valuing Outcomes

Policy, Organisation and Incentives in Health Systems

Value, Affordability and Decision Making
News

Events

Insights

Bulletin
Education Hub

OHE Graduate School

EVIA Programme
The Prize Fund

2024 Prize Fund

2022 Prize Fund

Events
About Us
OHE Experts
Join OHE
Contact Us

Newsletter SignupSubscribe

Filter results by

Theme

Select the product option you would like to filter Theme

Economics of Innovation Measuring and Valuing Outcomes Policy, Organisation and Incentives in Health Systems Value, Affordability, and Decision Making

Topic

Select the product option you would like to filter Topic

Antimicrobial Resistance (AMR) Biosimilars Cell and Gene Therapies Chronic Diseases Combination Therapies COVID-19 Research Digital Health Drug Development/R&D Emerging Markets EQ-5D and PROMs Health Care Systems Health Data and Statistics Health Technology Assessment (HTA) Innovation Policy Prize OHE Consulting Precision Medicine Prevention Real World Evidence (RWE) Research Sustainability Use of Medicines Vaccines Value-Based Pricing

Tag

Select the product option you would like to filter Tag

Adult Immunisation Cancer Cardiovascular Disorders Caring burden Cervical Cancer Clinical Outcomes Commentary Competition Dermatology Determining Value Economic Evaluation Egypt Epidemiology and Public Health Epilepsy Gene therapies Generics Greece Health Policy and Regulation Healthcare Delivery Healthcare Expenditure Healthcare Funding Healthcare System Pressure (HCSP) India Infectious Diseases Inflation Reduction Act Injury and Trauma Innovation Israel Market Access Mental Health Pharmaceutical Industry Plant-based Policy Analysis Pricing and Reimbursement Primary Care Quality of Care Quality of Life Rare and Orphan Diseases Research Funding Resource Allocation Saudi Arabia Slovak Republic Türkiye Vaccines Value based pricing Webinar

Date 1

Select the product option you would like to filter Date

Date From

Month From

Year From

Date To

Month To

Year To

Author

Select the product option you would like to filter Author

Search authors

Ramiro Gilardino Agnes Brandtmüller Melinda Goodall Katherine Nelson Julie Van Bavel Dr. Jacoline Bouvy Andrew Davies Dr. Matthijs Versteegh Thomas Allvin Dr. Cheong Wei Yang

Content Type

Select the product option you would like to filter Content Type

news story insight events podcast bulletin publications

Insight
March 2022

To Hell with the 3L! NICE’s Missed Opportunity to Upgrade Health Outcome Measurement

Insight
February 2022

Rare Disease Day 2022

Insight
February 2022

New NICE Manual for Health Technology Evaluations: A Critical Discussion on the Most Relevant Changes (or Lack Thereof)

Feb-Bulletin_greenbutterfly-scaled-e1673976289787-1

Bulletin
February 2022

February 2022

Insight
February 2022

How Does Pharmaceutical Spending Drive Innovation in Europe?

Past Event
OHE Webinar
January 2022

Do We Need Animal Health Economics?

2021 OHE Annual Report to the Charity Commission

Sustainability

Supporting the Era of Green Pharmaceuticals in the UK

News
January 2022

OHE Announces New Trustees and Board Chair

Bulletin
January 2022

January 2022

Drug Development/R&D
Economics of Innovation
Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

Cell and Gene Therapies
Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

Health Technology Assessment…
Measuring and Valuing Outcomes

Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies

News
December 2021

OHE Thanks Trustees for Their Service

Leading intellectual authority on global health economics

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Cookies Policy

An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Twitter

Facebook

Copy

Share on Mastodon

Enter your Mastodon instance URL (optional)

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

Enable or Disable Cookies

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Enable or Disable Cookies

Please enable Strictly Necessary Cookies first so that we can save your preferences!

News & Insights

Latest Research & Publications

Anchoring Latent Scale Values for the EQ-5D-Y at 0 = Dead

2018 OHE Annual Report to the Charity Commission

HTA and Payment Mechanisms for New Drugs to Tackle AMR

Data Governance Arrangements for Real-World Evidence in Japan

Unrelieved Pain in Palliative Care in England

The Case of Risperidone: Assessing the Life-cycle Value of Second-Generation Antipsychotics in Sweden and the UK

Valuing EQ-5D-Y Health States Using a Discrete Choice Experiment: Do Adult and Adolescent Preferences Differ?

Documento de debate sobre la fijación de precios en función de la indicación (IBP) ¿Deben variar los precios de los medicamentos según la indicación?

All Publications

Filter results by

To Hell with the 3L! NICE’s Missed Opportunity to Upgrade Health Outcome Measurement

Rare Disease Day 2022

New NICE Manual for Health Technology Evaluations: A Critical Discussion on the Most Relevant Changes (or Lack Thereof)

February 2022

How Does Pharmaceutical Spending Drive Innovation in Europe?

Do We Need Animal Health Economics?

2021 OHE Annual Report to the Charity Commission

Supporting the Era of Green Pharmaceuticals in the UK

OHE Announces New Trustees and Board Chair

January 2022

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies

OHE Thanks Trustees for Their Service

Share on Mastodon